Abiopharma

🔍 van der Kamp Hilde Johanna (Executive)

Company: NewAmsterdam Pharma Co N.V. (NAMS)

Report Date: 2026-01-07

Detailed Transactions and Holdings:

• Acquired 3,400 shares of Ordinary Shares (Direct)
  Date: 2026-01-07 | Code: A | equity_swap_involved: false | shares_owned_after: 10,360.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 15,300 shares of Option (right to buy) at $35.45 per share (Derivative)
  Date: 2026-01-07 | Code: A | Expires: 2036-01-07 | equity_swap_involved: false | shares_owned_after: 15,300.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.
• F2: Each RSU was granted on January 7, 2026 for no consideration.
• F3: All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.